BR0210631A - Composição farmacêutica de liberação prolongada - Google Patents

Composição farmacêutica de liberação prolongada

Info

Publication number
BR0210631A
BR0210631A BR0210631-0A BR0210631A BR0210631A BR 0210631 A BR0210631 A BR 0210631A BR 0210631 A BR0210631 A BR 0210631A BR 0210631 A BR0210631 A BR 0210631A
Authority
BR
Brazil
Prior art keywords
extended release
pharmaceutical composition
composition
release pharmaceutical
mini
Prior art date
Application number
BR0210631-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Serge R Martinod
Malcolm Brandon
Original Assignee
Smart Drug Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart Drug Systems Inc filed Critical Smart Drug Systems Inc
Publication of BR0210631A publication Critical patent/BR0210631A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0210631-0A 2001-06-29 2002-07-01 Composição farmacêutica de liberação prolongada BR0210631A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR6025A AUPR602501A0 (en) 2001-06-29 2001-06-29 Sustained release pharmaceutical composition
PCT/AU2002/000865 WO2003002102A1 (en) 2001-06-29 2002-07-01 Sustained release pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR0210631A true BR0210631A (pt) 2004-07-27

Family

ID=3829991

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210631-0A BR0210631A (pt) 2001-06-29 2002-07-01 Composição farmacêutica de liberação prolongada

Country Status (10)

Country Link
US (1) US20040241204A1 (enExample)
EP (1) EP1411904A4 (enExample)
JP (1) JP4800570B2 (enExample)
CN (1) CN1731988A (enExample)
AU (2) AUPR602501A0 (enExample)
BR (1) BR0210631A (enExample)
CA (1) CA2452030A1 (enExample)
CO (1) CO5540373A2 (enExample)
NZ (1) NZ529859A (enExample)
WO (1) WO2003002102A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
CN1638747A (zh) * 2002-01-24 2005-07-13 斯玛特药物系统公司 持续释放药物组合物
US20080044450A1 (en) * 2004-05-31 2008-02-21 Malcolm Brandon Sustained Release Composition
WO2005123120A1 (en) * 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
AU2005253646B2 (en) * 2004-06-16 2011-09-15 Virbac Corporation Sustained release vaccine composition
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
EP1859788A1 (en) * 2006-05-24 2007-11-28 Abbott GmbH & Co. KG Production of enveloped pharmaceutical dosage forms
NZ552290A (en) * 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
BRPI0705822A2 (pt) * 2007-10-25 2009-06-23 Schering Plough Saude Animal Ltda formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
CN102215901B (zh) * 2008-11-07 2014-12-03 联合生物医学系统有限公司 用于治疗和/或预防疾病的装置和方法
MX2011009678A (es) 2009-03-17 2011-09-30 Intervet Int Bv Sistema de suministro de farmaco de lactona macrociclica.
WO2011151386A1 (en) * 2010-06-01 2011-12-08 Baxter International Inc. Process for making dry and stable hemostatic compositions
HRP20190562T1 (hr) 2010-07-30 2019-06-14 CEVA Santé Animale SA Sastavi za liječenje zaraze srčanim crvom
JP5696279B2 (ja) * 2010-12-01 2015-04-08 学校法人自治医科大学 長期徐放型薬剤硬膜外腔留置システム
PL2785719T3 (pl) 2011-12-02 2018-03-30 Merial, Inc. Długodziałające wstrzykiwalne postaci moksydektyny i nowe postaci krystaliczne moksydektyny
US20130190839A1 (en) * 2012-01-20 2013-07-25 Jane Rapsey Drug delivery using a sacrificial host
WO2014160026A2 (en) * 2013-03-14 2014-10-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof
AU2013209343B1 (en) * 2013-05-14 2014-04-24 Activesignal Holding Limited Device for the Treatment of Bone Conditions
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
JP2021528452A (ja) * 2018-06-25 2021-10-21 タイタン ファーマシューティカルズ インコーポレイテッド インプラントとして使用するための装填可能な多孔質構造
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
CN110559431B (zh) * 2019-10-11 2023-02-28 南京农业大学 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用
CA3201057A1 (en) 2020-12-08 2022-06-16 Mark Christopher LAY Improvements to devices and methods for delivery of substances to animals
US20240238226A1 (en) * 2021-03-09 2024-07-18 Adnan I. Qureshi Implantable sustained release device and a method of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
ATE90203T1 (de) * 1989-03-17 1993-06-15 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
KR0141583B1 (ko) * 1989-06-21 1998-06-15 윌리암 엠. 잭슨 신경병 치료장치
FR2653338B1 (fr) * 1989-10-23 1994-06-10 Dow Corning Sa Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
EP0542915A1 (en) * 1990-08-09 1993-05-26 Endocon, Inc. Multiple drug delivery system
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
JPH06321803A (ja) * 1993-05-17 1994-11-22 Kirin Brewery Co Ltd 水溶性ペプチドホルモンの徐放性製剤
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
FR2745180B1 (fr) * 1996-02-23 1998-05-07 Dow Corning Sa Procede de fabrication de dispositifs a liberation controlee
BR9812385A (pt) * 1997-09-23 2000-09-12 Pfizer Formulações parasiticidas
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
IL140899A0 (en) * 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
GB9816132D0 (en) * 1998-07-24 1998-09-23 Norbrook Lab Ltd Non-aqueous anthelmintic composition
AU5532699A (en) * 1998-09-05 2000-03-27 Seung Jin Lee Biodegradable particulate polymeric preparation and process for producing thereof
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
AU6526100A (en) * 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
TW524696B (en) * 1999-11-10 2003-03-21 Sumitomo Pharma Sustained-release drug formulations
WO2001037811A1 (en) * 1999-11-22 2001-05-31 Akzo Nobel N.V. Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
US20020131988A1 (en) * 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix

Also Published As

Publication number Publication date
CA2452030A1 (en) 2003-01-09
AUPR602501A0 (en) 2001-07-26
AU2002344685B2 (en) 2008-05-15
US20040241204A1 (en) 2004-12-02
NZ529859A (en) 2005-11-25
CO5540373A2 (es) 2005-07-29
JP2004530721A (ja) 2004-10-07
EP1411904A4 (en) 2006-06-07
JP4800570B2 (ja) 2011-10-26
WO2003002102A1 (en) 2003-01-09
EP1411904A1 (en) 2004-04-28
CN1731988A (zh) 2006-02-08

Similar Documents

Publication Publication Date Title
BR0210631A (pt) Composição farmacêutica de liberação prolongada
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0115531A (pt) Tratamento de mucosites
ES2181691T3 (es) Sistema de distribucion de droga eritropoyetina.
BR0212052A (pt) Preparação de composição farmacêutica de liberação prolongada
MXPA05011517A (es) Dispositivo para el suministro de medicamentos oftalmicos.
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
ES2037082T3 (es) Una composicion para la liberacion controlada de un farmaco.
DK1037667T3 (da) Farmaceutiske hydrogelformuleringer, lægemiddelindgivelsesanordninger samt fremgangsmåder
BRPI0607483A2 (pt) microimplantes para administração ocular
BRPI0407747A (pt) agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6
DE60023520D1 (de) Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung
PT984774E (pt) Microesferas de libertacao controlada, com retencao gastrica, para uma administracao de drogas melhorada
ATE245450T1 (de) Haftende mikrokügelchen umfassende zusammensetzung zur arzneimittelgabe
BR0210630A (pt) Sistema fornecedor de liberação prolongada
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
PT770384E (pt) Composicoes farmaceuticas solidas anidras para utilizacao vaginal
DK0904063T3 (da) Fremgangsmåde til fremstilling af mikropartikler
DE69716469D1 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
CY1108482T1 (el) Συστημα υποδοριας διανομης, μεθοδος παρασκευης του και χρηση του για την αγωγη διαταραχων xολινεργικης ανεπαρκειας
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
CO5210863A1 (es) Medicamento para el tratamiento de urgencia urinaria incre- mentada o incontinencia urinaria . . . . .

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VIRBAC CORPORATION (US)

Free format text: TRANSFERIDO DE: SMART DRUG SYSTEMS INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2313 DE 05-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 31/365 (2006.01), A61K 3